Introduction

Definition of Follicular Lymphoma (FL)

It is a type of lymphoma, usually slow progressive disease resulting from the lump formation of white blood cells inside lymph nodes. It is represented as a 2nd type of lymphoma, abbreviated as NHL (non-Hodgkin lymphoma).¹

 It accounts for about 20-30 % of NHL, primarily known as the second most common NHL. It is generally classified as an indolent B-cell lymphoproliferative disorder, probably graded ranging from 1 as low to 3 as high based on histology.²

Importance of bone marrow involvement

Bone marrow involvement (BMI) can be detected at presentation in up to 70% of patients with FL, whereas involvement of other extranodal sites is infrequent. Determining BMI is important in the staging of lymphoma as it signifies advanced disease.³

Pathophysiology of Follicular Lymphoma

Genetic and molecular basis 

The molecular pathogenesis of FL includes the following factors:

• Diffuse large B-cell lymphoma (DLBCL) 
• Physiological germinal centre (GC) reaction
• Key factors like BCL2 and BCL6 gene translocations
• Deregulating apoptotic and transcriptional control
• Aberrant somatic hypermutation (aSHM)⁴

Histological features

• A tumour composed of sheet of large lymphoid cells represents DLBCL
• Tumour composed of an admixture of small and large lymphoid cells, establishing the diagnosis of HT is challenging
• HT to be described as a proportion of large lymphoma cells of ≥20% along diffuse pattern
• Diagnosis of challenging cases, Ki-67 index ≥50% is used as a reference⁵

Bone marrow involvement in Follicular Lymphoma

Mechanism of bone marrow infiltration

Bone marrow involvement BMI is known to relate to Ann Arbor system in direct or indirect manner also an important factor in most clinical risk stratification indices, including the International Prognostic Score (IPS) for advanced Hodgkin lymphoma, the International Prognostic Index (IPI) and its successors for aggressive non-Hodgkin lymphoma and diffuse large B-cell lymphoma (DLBCL) and the Follicular Lymphoma International Prognostic Index (FLIPI) and new FLIPI 2 for follicular lymphoma.⁶

Diagnostic approaches

Bone marrow biopsy 

A bone marrow biopsy is a diagnostic test procedure aimed to access sample of bone marrow for microscopic examination. Microscopic analysis of cells helps to differentiate between normal and abnormal cells named as lymphomas.⁸

Imaging techniques 

18-Fluoro-deoxyglucose positron emission tomography/computerised tomography (FDG PET/CT) an imaging technique used to analyse lymphomas and helpful in the management of patients with lymphomas and is recommended for both initial staging and response assessment after treatment in patients with diffuse large B-cell lymphoma and Hodgkin lymphomas.⁹

Prognostic implications

Prognostic factors 

Currently, we have only a few biological parameters that have been validated for defining prognosis in patients with FL currently being managed according to their clinical and laboratory features. The most prominent feature involved in defining treatment when a new FL patient being diagnosed with lymphoma are:

• Patient condition 
• Extent of disease⁷

Treatment strategies

Treatment options

• Monotherapy with rituximab: Rituximab represents a confident choice for patients known to be resistant from normal therapy, prescribed as a monotherapy in low-tumour-burden FL patients
• Front-line immunochemotherapy: Rituximab with combined chemotherapy has been proven efficacy in clinical trials, with improvements in response rates, time to progression or overall survival
• Salvage treatment: Prescribe in case of recurrent, relapsed and resistant lymphoma patients. Can be used in combination to others⁸

Management

The use of maintenance strategies after initial treatment in FL has been considered over a long time. Prescribed interferon was evaluated and showed effectiveness in terms of duration of remission and survival.⁸

Future directions and research

The following are some possible out comes for future study and research in follicular lymphoma:

• Personalised medicine: coming up with new personalised based on traits individualised according to each patient, such as protein expression and genetic variations
• Immunotherapy: Involved in examining novel immunotherapeutic strategies, such as CAR-T cell therapy and checkpoint inhibitors
• Stem cell transplantation: Examining how stem cell transplantation to be applied in follicular syndrome
• Gene editing: Changing the gene expression linked to follicular lymphoma by using CRISPR/Cas9 gene technologies
• Epigenetic modifiers: Examining epigenetic modifiers as possible targets for medication
• Combination therapies: Assessing regimens that combine both new and established medications
• Biomarker development: Identifying and validating biomarkers for diagnosis, prognosis, and treatment response prediction
• Minimal residual disease (MRD): Developing MRD detection methods to monitor treatment response and predict relapse
• Follicular lymphoma microenvironment: Examining treatment resistance is shown by which means that disease progression are influenced by the tumour microenvironment
• Clinical studies: Performing clinical studies in order to acess novel therapies and dosage plans

FAQs

What is follicular lymphoma (FL)?

FL is a type of lymphoma, usually a slow-progressing disease resulting from the lump formation of white blood cells inside lymph nodes.

What is the significance of bone marrow involvement (BMI) in FL?

BMI is important in the staging of lymphoma, signifies advanced disease, and can be detected at presentation in up to 70% of patients with FL.

What are the diagnostic approaches for detecting BMI in FL?

Diagnostic approaches include bone marrow biopsy and imaging techniques like FDG PET/CT.

What are the treatment options for FL?

Treatment options include monotherapy with rituximab, front-line immunochemotherapy, and salvage therapy.

What are the prognostic implications of BMI in FL?

BMI is a significant prognostic factor, and its detection can guide treatment decisions.

What are the future directions and research areas in FL?

Future directions include personalised medicine, immunotherapy, gene editing, and biomarker development.

Summary

The slow-growing lymphoma known as follicular lymphoma (FL) frequently involves the bone marrow (BMI). It is evident to comprehend the pathophysiology, diagnostic techniques, and therapy plans to manage FL in regards to symptoms and support care.For the purpose of determining BMI, bone marrow biopsy and imaging methods such as FDG PET/CT are required. Prognostic variables, such as clinical and laboratory characteristics, dictate therapy options. Salvage therapy, front-line immunochemotherapy, and monotherapy are most common and highly used treatment options that are available in the market.

Future directions and maintenance approaches that show promise for bettering FL management include gene editing, immunotherapy, and personalised medication. To create efficient therapies and biomarkers for diagnosis, prognosis, and therapy response prediction, further research is required.